UY28653A1 - N-alquil pirroles como inhibidores de la hmg-coa reductasa - Google Patents

N-alquil pirroles como inhibidores de la hmg-coa reductasa

Info

Publication number
UY28653A1
UY28653A1 UY28653A UY28653A UY28653A1 UY 28653 A1 UY28653 A1 UY 28653A1 UY 28653 A UY28653 A UY 28653A UY 28653 A UY28653 A UY 28653A UY 28653 A1 UY28653 A1 UY 28653A1
Authority
UY
Uruguay
Prior art keywords
hmg
pirroles
rent
inhibitors
compounds
Prior art date
Application number
UY28653A
Other languages
English (en)
Inventor
Larry Don Bratton
Chitase Lee
Bharat Kalidas Trivedi
Steven Robert Miller
Jeffrey Allen Pfeferkorn
Roderick Joseph Sorenson
Yuntao Song
Kuai-Lin Sun
Paul Charles Unangst
Toni-Jo Poel
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of UY28653A1 publication Critical patent/UY28653A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Se proporcionan compuestos inhibidores de la HMG Co-A reductasa útiles como compuestos hipocolesterolémicos e hipolopedémicos. También se proporcionan composiciones farmacneuticas de los compuestos. También se proporcioann métodos para fabricar y métodos para usar los compuestos.
UY28653A 2003-12-05 2004-12-03 N-alquil pirroles como inhibidores de la hmg-coa reductasa UY28653A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52734703P 2003-12-05 2003-12-05
US60194304P 2004-08-16 2004-08-16
US62110104P 2004-10-25 2004-10-25

Publications (1)

Publication Number Publication Date
UY28653A1 true UY28653A1 (es) 2005-07-29

Family

ID=34682163

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28653A UY28653A1 (es) 2003-12-05 2004-12-03 N-alquil pirroles como inhibidores de la hmg-coa reductasa

Country Status (12)

Country Link
US (1) US20050154042A1 (es)
EP (1) EP1691803A1 (es)
JP (1) JP2007513144A (es)
AR (1) AR047628A1 (es)
BR (1) BRPI0417138A (es)
CA (1) CA2547573A1 (es)
MX (1) MXPA06005915A (es)
NL (1) NL1027655C2 (es)
PE (1) PE20050590A1 (es)
TW (1) TW200526575A (es)
UY (1) UY28653A1 (es)
WO (1) WO2005056004A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
CA2623043A1 (en) * 2005-09-19 2007-04-12 F. Hoffman-La Roche Ag Isoxazolo derivatives as gaba a alpha5 inverse agonists
MX2008008470A (es) 2005-12-27 2008-09-26 Univ Pais Vasco Nuevos derivados pirrolicos con actividad inhibidora de desacetilasa de histonas.
WO2007146823A2 (en) * 2006-06-08 2007-12-21 Pro-Pharmaceuticals, Inc. Carbohydrate derivatives of heptanoic acids
US20110295005A1 (en) * 2007-08-20 2011-12-01 Ratiopharm Gmbh Process for preparing pyrimidine derivatives
EP2305643A1 (en) * 2009-10-02 2011-04-06 Ikerchem, S.L. New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers
US8530653B2 (en) * 2009-11-06 2013-09-10 Chelsea Therapeutics, Inc. Enzyme inhibiting compounds
CN102250040A (zh) * 2011-06-01 2011-11-23 华东理工大学 N-(3’-芳基烯丙基)吡咯衍生物的制备方法
ITVI20130039A1 (it) 2013-02-20 2014-08-21 F I S Fabbrica Italiana Sint I S P A Processo per la preparazione di intermedi chiave per la sintesi di statine
WO2023249481A1 (en) * 2022-06-21 2023-12-28 Petroliam Nasional Berhad (Petronas) Ashless ionic liquid

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049495A (en) * 1974-06-07 1977-09-20 Sankyo Company Limited Physiologically active substances and fermentative process for producing the same
JPS5612114B2 (es) * 1974-06-07 1981-03-18
DE2748825C2 (de) * 1976-11-02 1986-11-27 Sankyo Co., Ltd., Tokio/Tokyo Substituierte 3,5-Dihydroxyheptansäurederivate und diese enthaltende Arzneimittel gegen Hyperlipämie
JPS53147073A (en) * 1977-05-24 1978-12-21 Sankyo Co Ltd Mevalonolactone derivatives
JPS5559180A (en) * 1978-10-30 1980-05-02 Sankyo Co Ltd 4-hydroxy-2-pyrone ring compound, its preparation, and remedy for hyperlipemia comprising it as active constituent
US4375475A (en) * 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4851427A (en) * 1985-10-25 1989-07-25 Sandoz Pharm. Corp. Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
DE3817808A1 (de) * 1987-07-21 1989-02-02 Bayer Ag Verfahren zur herstellung von 2-substituierten pyrrolen
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
PT1148049E (pt) * 1995-07-17 2005-02-28 Warner Lambert Co Formas cristalinas de hemi-sal de calcio do acido [r-(r*,r*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil)-1h-pirrole-1-heptanoico (atorvastatina)

Also Published As

Publication number Publication date
NL1027655A1 (nl) 2005-06-07
AR047628A1 (es) 2006-02-01
CA2547573A1 (en) 2005-06-23
PE20050590A1 (es) 2005-09-05
JP2007513144A (ja) 2007-05-24
TW200526575A (en) 2005-08-16
MXPA06005915A (es) 2006-06-27
NL1027655C2 (nl) 2005-11-15
US20050154042A1 (en) 2005-07-14
WO2005056004A1 (en) 2005-06-23
EP1691803A1 (en) 2006-08-23
BRPI0417138A (pt) 2007-02-21

Similar Documents

Publication Publication Date Title
BRPI0413468A (pt) inibidores de hmg-coa redutase baseados em pirrol
BRPI0509926A (pt) imidazóis
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
DK1223918T3 (da) Farmaceutiske præparater omfattende en HMG-CoA-reductaseinhibitor
EA200800321A1 (ru) Ингибиторы гистондеацетилазы
ATE471324T1 (de) Triazolophthalazine
EA201100689A1 (ru) N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
EA200500201A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
EA201270630A1 (ru) Гетероциклические сетр ингибиторы
CR8111A (es) Derivados sustituidos del pirrol
TW200738649A (en) Calcilytic compounds
BRPI0506865A (pt) inibidores de hmg-coa redutase inusitados, baseados em imidazóis
EA200800070A1 (ru) Производные 2-(1h-индолилсульфанил)ариламина
NO20063293L (no) Farmasoytiske forbindelser
UY28653A1 (es) N-alquil pirroles como inhibidores de la hmg-coa reductasa
UY30801A1 (es) Compuestos calciliticos
AU2003250172A1 (en) Compositions comprising hmg-coa reductase inhibitor
AU2003239508A1 (en) Indole compounds useful as impdh inhibitors
CY1111768T1 (el) Νεος παραγοντας μειωσης τριγλυκεριδιου
EA200500204A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
DE60233899D1 (de) Neue boronatester
DOP2004001043A (es) N-alquil pirroles como inhibidores de la hmg-coa reductasa
PA8619201A1 (es) N-alquil pirroles como inhibidores de la hmg-coa reductasa
AU2002331362A1 (en) New alkynylated quinazolin compounds as mmp-13 inhibitors
DOP2005000063A (es) Nuevos imidazoles

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150609